{"ticker": {"uuid": "52e0e6c4-6cfc-4cd8-99c9-2c55744073a1", "symbol": "RNA", "name": "Atrium Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Atrium Therapeutics\u2019 new hire receives options and 3,500 stock units", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPa1FWVThWTXRWZlNwS3d1QWFvaDZkLVg3c09tLXdZemN3Q0xIRUQ4X3FhbWFNN0FHNnBxZEY4cGlwZTVwMlJYTkp1UFpNSjZUSS1ld3EtSjc0QU1pS09XM21DT0VSeVM1TFU2TzJjVldLLWNtQVV4d0hsQWZpWE9QNTFQdDlqanhrXzNUVmhjZWlvSkRYWDVDR2RIaGxHcFFTMkFrbkh1S0VsSkRiT3ZRa3l6TndYVWRyUGFhWFFsMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T21:58:00+00:00", "published_display": "20 Jul 2026 21:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQMDV6R0RaTUdqc052djFrdTJwTlhUdU1Db2pabGZQVWZkLXR0dlpuSmFLd3hibE4xWEVKTFJ4WTQwUnAybzEtN2xZYTVsUWhmbUdad2NEMEM1WDFmckFxTFh5Z0RXSVpNMGt2OVMzeG1vQ05kUWlXM210dTYyTm94VFo5TVFnMmI1LXNIS05KLTM0QXdkN1NPNlBkQ2tGMzREWC1VMkNGUWlOc1NKaWZQSA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T21:15:00+00:00", "published_display": "14 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-says-fda-clears-111844254.html", "source_name": "MT Newswires", "published_at": "2026-07-14T11:18:44+00:00", "published_display": "14 Jul 2026 11:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-announces-fda-clearance-103000185.html", "source_name": "PR Newswire", "published_at": "2026-07-14T10:30:00+00:00", "published_display": "14 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium's First PRKAG2 Trial to Evaluate Treatment for Disease Cause", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOQWNaLWlHaXNsSVB6TkdGTnVhNWlGLVYyVE1YN01CVkhFeWt2bjFTVTRlSzdQUDY0YXZwX3pfRjBqUUk5b0lfakZNaGp4U1VNN3ZqMS1WdlJXM1E4cVVKX0JCazdUOXZ5X3U0a3djdE9sdjF5Rm44UlJVcVd3SjJSM21jeVVKVmdHMzZTOVlKVkNhUHhxWW5zUW5BTUt5QTFYMU9yTW9ETGpOOEZBVXZhR3dTamt5X29kRllIZA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T10:30:00+00:00", "published_display": "14 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBIT forward of Atrium Therapeutics, Inc. \u2013 NASDAQ:RNA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPRDE3bkRyd3Z4N3V1eFlXcXFzTC1paHJjQ2tiNFJxQ2FjZnpvb29yRE05dERpSk0zQVg3cTRxSnpVWFFUS3U2VmptelE5SVlKQnlxby1CX3NpU1ZPaGJNVHRjVG8wcU1GZzEzUUZ4cG5LMmpVbGhBUzh5Q2pkN1hEeGxub0d5OEdrSWFIdksxUDVORURlc2ZvbzhXUVA0VHd3N0d5ZmNmcE9Ndw?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T15:25:02+00:00", "published_display": "10 Jul 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPSjE2VWxPUV9KQ1BJUmswSWVhdmJIcVpRVmtINkJ2Q1plTDFEczRNVHFuOHo3OE9vM0NsOG5aMmpOTzZuVmdDWUp5RHBpdlBaRE4wWEd1Y1gyb252RThTN1BkY0JnTVY3Z2UwSlpwR0t4bl9IemlmdUNTYk9iMmV2dl90aUptb3hKcS1nOGNONWdfU2hSUGc1N0FmcUVuTmREUDdVei1aaXljVDBBLUZEUzl1bGVfRmF2UzZkUW51bnMwOXEyemstMjlxaXhBaThuVEE?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics awards stock grants to 8 new hires", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPR3g2Y1VsMnBodV82b214VGpHMUNBaE5ZZWVxXzdyV3VjN3hpOGZPS011YnN5ZnhsTWdBczdBT2dwZXF0Q0lnTEtmYjU5OU12Wml3ekdhaGs1ZUNvdVJ1MWJVV1lxbWpaUkhoWXN6aTRaVVIxb0hiVzZ1NVFqb1h1dDhFTUh2YTUwdENWOVljcENsd1NOU3hBQkoyZml6T2s3dTZrVmQ1cEp3V1A0ZGtBLU1IT1NvdnY3V0tFOE1HTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Stock - Long-term strategy around RNA therapeutics", "summary": "This article focuses on Avidity Biosciences' long-term strategy, clinical pipeline, and funding status as a pre-commercial biotechnology company. The company specializes in developing RNA-based therapies for rare muscle and neuromuscular diseases using antibody-oligonucleotide co", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/avidity-biosciences-stock-long-term-strategy-around-rna-therapeutics/69590338", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T14:47:43", "published_display": "20 Jun 2026 14:47", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Inc (RNA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Avidity Biosciences Inc (RNA), highlighting its current earnings forecast score of 8.00 and an average price target of $72.00, with an upside of 96.08%. Based on analytics from 2 analysts, the stock receives a \"Strong Buy\" rating. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rna/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:37", "published_display": "19 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Inc (RNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Avidity Biosciences Inc (RNA), detailing its business segments, regional revenue, and profit contribution. It shows that the company's revenue from the United States was $18.62 million, with segment and regional data not yet fully dis", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rna/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:51", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNY3k2a3E5TUhXZzQ4Mlp1bElBNmxjUEd5U2I2eDBDNkl3WDdWN3Ywc0FfMVBVckc5SWFoOEJKMjlzSDY3cU85V0RxZVJ3U0laSElPSUp0dW5Jd3JGRG5sRzRMN1V6R0l4bllaenU5bTFxWjRfY01ZYndDdGRuUjRlaUFCTUJmNHphalZtby1LemI?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Price Target Announced at $25.00/Share by Leerink Partners", "summary": "Leerink Partners has set a price target of $25.00 per share for Avidity Biosciences (NASDAQ: RNA). This new target suggests a potential for significant movement in the company's stock, according to the analyst firm. Investors will likely be watching how Avidity Biosciences reacts", "url": "https://www.moomoo.com/news/post/70111841/avidity-biosciences-price-target-announced-at-25-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-15T21:39:44", "published_display": "15 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Atrium Therapeutics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZkZuN1R5MnhYWnZrT3ozWG9xTE1Jb0F5Y0o4NnRfbmhTNVpoZXBoWkZDYm5Ddi1YRndjcnI3UVBkcGN5VGFOTGgwSDc3WFhxVjhrT2xNc0pMdWQ2aFEtRFhWTkxWNjdLLVRkMkw5R0NHVHlsSThmYXdfLUs2bG5TSTFyczNtaloyT2FlbU1Zc1hPdmMzaFJNeWFkRXhrUndxWm1HbkYzazVzMEp3UUJFUGx3ZmRxd2lOTFdyWQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Novartis acquisition spin-off pioneers RNA therapeutics for the heart", "summary": "Atrium Therapeutics, a spin-off from Avidity Biosciences following its acquisition by Novartis, is pioneering precision RNA therapeutics for rare, genetic cardiomyopathies. The company, launched with $270 million in funding and a Novartis-validated delivery platform, aims to deve", "url": "https://www.pharmavoice.com/news/novartis-avidity-atrium-spinoff-rna-heart/815050/", "source_name": "Pharma Voice", "published_at": "2026-03-19T14:11:52", "published_display": "19 Mar 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis, Avidity Deal Spins Out New RNA Co.", "summary": "Atrium Therapeutics, a new RNA company, launched in February with $270 million in funding as a spinoff following Novartis' $12 billion acquisition of Avidity Biosciences. Atrium will focus on developing RNA therapeutics for rare muscle diseases, particularly in the precision card", "url": "https://www.sdbj.com/life-sciences/biotech-life-sciences/novartis-avidity-deal-spins-out-new-rna-co/", "source_name": "San Diego Business Journal", "published_at": "2026-03-09T11:52:10", "published_display": "09 Mar 2026 11:52", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNAM SEC Filings - Avidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to Avidity Biosciences's (Ticker: RNAM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores from Rhea-AI, and end-of-day stock performance data to offer insights into market r", "url": "https://www.stocktitan.net/sec-filings/RNAM/", "source_name": "Stock Titan", "published_at": "2026-03-09T10:52:06", "published_display": "09 Mar 2026 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis", "summary": "This article reports that Avidity Biosciences (RNA) saw its stock price reach an all-time high due to rumors of a potential $12-billion merger with Novartis. This speculative news has significantly boosted investor confidence in RNA.", "url": "https://www.msn.com/en-us/money/companies/avidity-biosciences-rna-soars-to-all-time-high-on-looming-12-billion-merger-with-novartis/ar-AA1Pkpba?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-03-09T09:52:37", "published_display": "09 Mar 2026 09:52", "sentiment": "positive", "sentiment_pct": 91, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics born from Novartis-Avidity deal to pioneer RNA therapies", "summary": "Atrium Therapeutics has launched as an independent publicly traded company, spun off from Novartis' acquisition of Avidity Biosciences. The new company aims to develop RNA therapies for rare and life-threatening genetic cardiomyopathies, leveraging approximately $270 million in c", "url": "https://www.bioxconomy.com/partnering/atrium-therapeutics-born-from-novartis-avidity-deal-to-pioneer-rna-therapies", "source_name": "BioXconomy", "published_at": "2026-03-04T04:40:09", "published_display": "04 Mar 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of \"Hold\" from Analysts", "summary": "Avidity Biosciences, Inc. (NASDAQ:RNA) has received an average \"Hold\" rating from twenty-one analysts, with an average 12-month price target of $69.57. Recent insider selling of 58,407 shares worth $4.23 million was noted, alongside a Q3 earnings miss where EPS of ($1.59) and rev", "url": "https://www.marketbeat.com/instant-alerts/avidity-biosciences-inc-nasdaqrna-receives-average-rating-of-hold-from-analysts-2026-03-03/", "source_name": "MarketBeat", "published_at": "2026-03-03T09:52:57", "published_display": "03 Mar 2026 09:52", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNN0hNMjgzanhNdV8weGJZNWw4RmZNMWt4QW8tQXYwbFZqZXFlM2tYOUdHdkRRbnZYeHNiNW55QU9pQVQ1di1UaGhwZEdzb1RhXzlaSjA0Sjk2Y2FuQVF1S1FlVVFTcHBZdXRJRG9CckRKLTVUOC1OSVNWX2o2dnd0T2drYkJnTEhUUjJLYkVSWW9RNjd2X2FrQzA3VEs5Y1d2YlNadF90eHVEQTJRcmVmTnhUd2pzYjNiTzNTZTlNdEk?oc=5", "source_name": "MedCity News", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPUVhEZ3RZME5xZkxBY0xKRDVyM2FkVnItR2cxWGtxaEJNQnVkMjA5bjg0SkdqX2JLUGNuYVpZUDgtRlNLTEJUdG9BNm53QW9oeWFNcUVRR0V1QzkxNzR6cVhCbXRDVzFVbDV2bURtZWxnUS1nbWFxRzlwLUUyeGxvMzlaQW1XRG9MTElMZEVQdDVmZUNuRVdmdlhwWF9HVWl0M1ctVDFEWE56ZzJYVXJ5SjU0QXdyTWVxWkY2em9FVlBMMHlXNlJwaDEwTF9aWkNuWnNmcm9B?oc=5", "source_name": "Trefis", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$RNA stock is down 80% today. Here's what we see in our data. | RNA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQd0NqTGQwSDY5UVNOTURPZmc1R25YXzhqVkdJeUtieDNfeDNwT19HRXl2VktOTTFvWFFnS2I4Ty03ZHNVY0FKMGxndFlMajNqbExzZlR4VzFkWHFIUGpyWWdGYUg3VktEX1RnbFc2eUY4YVQ0dXpFZXd2bDlVZEwwZ1VONjlDVkNIQTNFTzhDMnVnVEdIbm05N3hVLXJUSXBsMnc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxNWUlSMl8xSkFnU2RYU0Y1RkxHeDZFTm1OTHp1V2wwam1LdmZnUFVDc3JNN2lOSk5icE0ycHR6RzJMNEl5VElWT1huOVJ0S0NvV3lZbk1feUI3SzB6bzBHVDFva04tdnpqSmYzOXdFbG1US0trQndfWVA4MDBwYVEyUkdlUlZjVEx1em9zc2pZSzFZTlZaU1pnZjFncWxvRXVwX09abk9jTjEwcXMybUtfN2RFbDNuSEp3VHdJWng2NmlueEoyS0MxV0cxLUFUd0t3WjRPdThtd2JMWGJIX3Bhekg2SC15MW9VVmJVLUVFZGVXRmxwMW1CY3QyZTRzc1VEV3B6YW5CM25nN2E5RnpHNFZRV1BGWTlpcWstX3BXQjVjU1ZEbzEtY1o4VzIxY2xRUkxlR0hIU21yQTNjdEE?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-15T07:00:00+00:00", "published_display": "15 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPeFhRUF8wT0VzcmNQSlVTUlE5eEpuMzdTWFE4QkJfaVlnMGt4QU5CcHdHSDYyaHh3Q1lDZ1FuZXlsQjQ4V0k3R3B3V21iMG5fZVlUSjJYS3hNTFJGMUFpdUpnN2lmenJlZkszeDh0Rm55UmZJV0RHWFNhdVAxaEktTmRrSUNNa1hWa0l2eG51VXZqWlVKWnVkdWc0WVptUnZVNVJOZXN2UFJVSkZfNkREdlJ3ako3cU44cGpRRWFhNVhHakZy?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9ELTZtY1Z1Y0VsTHhQZWkwaWFfTUpvS21fUDhGU3M3c0Y1TDdGdGgzV2tmeXluUkNXZkVDdzRkU2JtWHdvX1N4V0pwU3VGb1dlVl9qbUlCekpRMzhDaXdMa05HaGFrdnBfTDFBcWZOZmd3WHZGZ091RA?oc=5", "source_name": "Market source", "published_at": "2025-08-25T07:00:00+00:00", "published_display": "25 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Atrium Therapeutics\u2019 new hire receives options and 3,500 stock units", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPa1FWVThWTXRWZlNwS3d1QWFvaDZkLVg3c09tLXdZemN3Q0xIRUQ4X3FhbWFNN0FHNnBxZEY4cGlwZTVwMlJYTkp1UFpNSjZUSS1ld3EtSjc0QU1pS09XM21DT0VSeVM1TFU2TzJjVldLLWNtQVV4d0hsQWZpWE9QNTFQdDlqanhrXzNUVmhjZWlvSkRYWDVDR2RIaGxHcFFTMkFrbkh1S0VsSkRiT3ZRa3l6TndYVWRyUGFhWFFsMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-20T21:58:00+00:00", "published_display": "20 Jul 2026 21:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQMDV6R0RaTUdqc052djFrdTJwTlhUdU1Db2pabGZQVWZkLXR0dlpuSmFLd3hibE4xWEVKTFJ4WTQwUnAybzEtN2xZYTVsUWhmbUdad2NEMEM1WDFmckFxTFh5Z0RXSVpNMGt2OVMzeG1vQ05kUWlXM210dTYyTm94VFo5TVFnMmI1LXNIS05KLTM0QXdkN1NPNlBkQ2tGMzREWC1VMkNGUWlOc1NKaWZQSA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T21:15:00+00:00", "published_display": "14 Jul 2026 21:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-says-fda-clears-111844254.html", "source_name": "MT Newswires", "published_at": "2026-07-14T11:18:44+00:00", "published_display": "14 Jul 2026 11:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-announces-fda-clearance-103000185.html", "source_name": "PR Newswire", "published_at": "2026-07-14T10:30:00+00:00", "published_display": "14 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium's First PRKAG2 Trial to Evaluate Treatment for Disease Cause", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOQWNaLWlHaXNsSVB6TkdGTnVhNWlGLVYyVE1YN01CVkhFeWt2bjFTVTRlSzdQUDY0YXZwX3pfRjBqUUk5b0lfakZNaGp4U1VNN3ZqMS1WdlJXM1E4cVVKX0JCazdUOXZ5X3U0a3djdE9sdjF5Rm44UlJVcVd3SjJSM21jeVVKVmdHMzZTOVlKVkNhUHhxWW5zUW5BTUt5QTFYMU9yTW9ETGpOOEZBVXZhR3dTamt5X29kRllIZA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T10:30:00+00:00", "published_display": "14 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Atrium Therapeutics, Inc. \u2013 NASDAQ:RNA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPRDE3bkRyd3Z4N3V1eFlXcXFzTC1paHJjQ2tiNFJxQ2FjZnpvb29yRE05dERpSk0zQVg3cTRxSnpVWFFUS3U2VmptelE5SVlKQnlxby1CX3NpU1ZPaGJNVHRjVG8wcU1GZzEzUUZ4cG5LMmpVbGhBUzh5Q2pkN1hEeGxub0d5OEdrSWFIdksxUDVORURlc2ZvbzhXUVA0VHd3N0d5ZmNmcE9Ndw?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T15:25:02+00:00", "published_display": "10 Jul 2026 15:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPSjE2VWxPUV9KQ1BJUmswSWVhdmJIcVpRVmtINkJ2Q1plTDFEczRNVHFuOHo3OE9vM0NsOG5aMmpOTzZuVmdDWUp5RHBpdlBaRE4wWEd1Y1gyb252RThTN1BkY0JnTVY3Z2UwSlpwR0t4bl9IemlmdUNTYk9iMmV2dl90aUptb3hKcS1nOGNONWdfU2hSUGc1N0FmcUVuTmREUDdVei1aaXljVDBBLUZEUzl1bGVfRmF2UzZkUW51bnMwOXEyemstMjlxaXhBaThuVEE?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics awards stock grants to 8 new hires", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPR3g2Y1VsMnBodV82b214VGpHMUNBaE5ZZWVxXzdyV3VjN3hpOGZPS011YnN5ZnhsTWdBczdBT2dwZXF0Q0lnTEtmYjU5OU12Wml3ekdhaGs1ZUNvdVJ1MWJVV1lxbWpaUkhoWXN6aTRaVVIxb0hiVzZ1NVFqb1h1dDhFTUh2YTUwdENWOVljcENsd1NOU3hBQkoyZml6T2s3dTZrVmQ1cEp3V1A0ZGtBLU1IT1NvdnY3V0tFOE1HTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Stock - Long-term strategy around RNA therapeutics", "summary": "This article focuses on Avidity Biosciences' long-term strategy, clinical pipeline, and funding status as a pre-commercial biotechnology company. The company specializes in developing RNA-based therapies for rare muscle and neuromuscular diseases using antibody-oligonucleotide co", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/avidity-biosciences-stock-long-term-strategy-around-rna-therapeutics/69590338", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T14:47:43", "published_display": "20 Jun 2026 14:47", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Inc (RNA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Avidity Biosciences Inc (RNA), highlighting its current earnings forecast score of 8.00 and an average price target of $72.00, with an upside of 96.08%. Based on analytics from 2 analysts, the stock receives a \"Strong Buy\" rating. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rna/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:37", "published_display": "19 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Inc (RNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Avidity Biosciences Inc (RNA), detailing its business segments, regional revenue, and profit contribution. It shows that the company's revenue from the United States was $18.62 million, with segment and regional data not yet fully dis", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rna/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:51", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWkdoUDRJdkh3QndoZ3J2OHBvOEJlMUFEYjc1X3pLZGFXUlJ6eS1iNXhpYzNyd1NSZGxPOUdDM0xnZW9RcS1kdWNwR0xydVFVcEFGVmhfWWF5SFhYTmR5dXM0cTRIUENtbTc5bUpuNTNZQ0h0QWhMbnZDdGpfYjRWM2c3SWlCOHVJYTVoaUdDYnk2cTRKWWZTZHFvXzZDMTFmOGRUUUhyX3J6RUE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNY3k2a3E5TUhXZzQ4Mlp1bElBNmxjUEd5U2I2eDBDNkl3WDdWN3Ywc0FfMVBVckc5SWFoOEJKMjlzSDY3cU85V0RxZVJ3U0laSElPSUp0dW5Jd3JGRG5sRzRMN1V6R0l4bllaenU5bTFxWjRfY01ZYndDdGRuUjRlaUFCTUJmNHphalZtby1LemI?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Price Target Announced at $25.00/Share by Leerink Partners", "summary": "Leerink Partners has set a price target of $25.00 per share for Avidity Biosciences (NASDAQ: RNA). This new target suggests a potential for significant movement in the company's stock, according to the analyst firm. Investors will likely be watching how Avidity Biosciences reacts", "url": "https://www.moomoo.com/news/post/70111841/avidity-biosciences-price-target-announced-at-25-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-15T21:39:44", "published_display": "15 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZkZuN1R5MnhYWnZrT3ozWG9xTE1Jb0F5Y0o4NnRfbmhTNVpoZXBoWkZDYm5Ddi1YRndjcnI3UVBkcGN5VGFOTGgwSDc3WFhxVjhrT2xNc0pMdWQ2aFEtRFhWTkxWNjdLLVRkMkw5R0NHVHlsSThmYXdfLUs2bG5TSTFyczNtaloyT2FlbU1Zc1hPdmMzaFJNeWFkRXhrUndxWm1HbkYzazVzMEp3UUJFUGx3ZmRxd2lOTFdyWQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis acquisition spin-off pioneers RNA therapeutics for the heart", "summary": "Atrium Therapeutics, a spin-off from Avidity Biosciences following its acquisition by Novartis, is pioneering precision RNA therapeutics for rare, genetic cardiomyopathies. The company, launched with $270 million in funding and a Novartis-validated delivery platform, aims to deve", "url": "https://www.pharmavoice.com/news/novartis-avidity-atrium-spinoff-rna-heart/815050/", "source_name": "Pharma Voice", "published_at": "2026-03-19T14:11:52", "published_display": "19 Mar 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novartis, Avidity Deal Spins Out New RNA Co.", "summary": "Atrium Therapeutics, a new RNA company, launched in February with $270 million in funding as a spinoff following Novartis' $12 billion acquisition of Avidity Biosciences. Atrium will focus on developing RNA therapeutics for rare muscle diseases, particularly in the precision card", "url": "https://www.sdbj.com/life-sciences/biotech-life-sciences/novartis-avidity-deal-spins-out-new-rna-co/", "source_name": "San Diego Business Journal", "published_at": "2026-03-09T11:52:10", "published_display": "09 Mar 2026 11:52", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNAM SEC Filings - Avidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to Avidity Biosciences's (Ticker: RNAM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores from Rhea-AI, and end-of-day stock performance data to offer insights into market r", "url": "https://www.stocktitan.net/sec-filings/RNAM/", "source_name": "Stock Titan", "published_at": "2026-03-09T10:52:06", "published_display": "09 Mar 2026 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis", "summary": "This article reports that Avidity Biosciences (RNA) saw its stock price reach an all-time high due to rumors of a potential $12-billion merger with Novartis. This speculative news has significantly boosted investor confidence in RNA.", "url": "https://www.msn.com/en-us/money/companies/avidity-biosciences-rna-soars-to-all-time-high-on-looming-12-billion-merger-with-novartis/ar-AA1Pkpba?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-03-09T09:52:37", "published_display": "09 Mar 2026 09:52", "sentiment": "positive", "sentiment_pct": 91, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics born from Novartis-Avidity deal to pioneer RNA therapies", "summary": "Atrium Therapeutics has launched as an independent publicly traded company, spun off from Novartis' acquisition of Avidity Biosciences. The new company aims to develop RNA therapies for rare and life-threatening genetic cardiomyopathies, leveraging approximately $270 million in c", "url": "https://www.bioxconomy.com/partnering/atrium-therapeutics-born-from-novartis-avidity-deal-to-pioneer-rna-therapies", "source_name": "BioXconomy", "published_at": "2026-03-04T04:40:09", "published_display": "04 Mar 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of \"Hold\" from Analysts", "summary": "Avidity Biosciences, Inc. (NASDAQ:RNA) has received an average \"Hold\" rating from twenty-one analysts, with an average 12-month price target of $69.57. Recent insider selling of 58,407 shares worth $4.23 million was noted, alongside a Q3 earnings miss where EPS of ($1.59) and rev", "url": "https://www.marketbeat.com/instant-alerts/avidity-biosciences-inc-nasdaqrna-receives-average-rating-of-hold-from-analysts-2026-03-03/", "source_name": "MarketBeat", "published_at": "2026-03-03T09:52:57", "published_display": "03 Mar 2026 09:52", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNN0hNMjgzanhNdV8weGJZNWw4RmZNMWt4QW8tQXYwbFZqZXFlM2tYOUdHdkRRbnZYeHNiNW55QU9pQVQ1di1UaGhwZEdzb1RhXzlaSjA0Sjk2Y2FuQVF1S1FlVVFTcHBZdXRJRG9CckRKLTVUOC1OSVNWX2o2dnd0T2drYkJnTEhUUjJLYkVSWW9RNjd2X2FrQzA3VEs5Y1d2YlNadF90eHVEQTJRcmVmTnhUd2pzYjNiTzNTZTlNdEk?oc=5", "source_name": "MedCity News", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPUVhEZ3RZME5xZkxBY0xKRDVyM2FkVnItR2cxWGtxaEJNQnVkMjA5bjg0SkdqX2JLUGNuYVpZUDgtRlNLTEJUdG9BNm53QW9oeWFNcUVRR0V1QzkxNzR6cVhCbXRDVzFVbDV2bURtZWxnUS1nbWFxRzlwLUUyeGxvMzlaQW1XRG9MTElMZEVQdDVmZUNuRVdmdlhwWF9HVWl0M1ctVDFEWE56ZzJYVXJ5SjU0QXdyTWVxWkY2em9FVlBMMHlXNlJwaDEwTF9aWkNuWnNmcm9B?oc=5", "source_name": "Trefis", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$RNA stock is down 80% today. Here's what we see in our data. | RNA Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQd0NqTGQwSDY5UVNOTURPZmc1R25YXzhqVkdJeUtieDNfeDNwT19HRXl2VktOTTFvWFFnS2I4Ty03ZHNVY0FKMGxndFlMajNqbExzZlR4VzFkWHFIUGpyWWdGYUg3VktEX1RnbFc2eUY4YVQ0dXpFZXd2bDlVZEwwZ1VONjlDVkNIQTNFTzhDMnVnVEdIbm05N3hVLXJUSXBsMnc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxNWUlSMl8xSkFnU2RYU0Y1RkxHeDZFTm1OTHp1V2wwam1LdmZnUFVDc3JNN2lOSk5icE0ycHR6RzJMNEl5VElWT1huOVJ0S0NvV3lZbk1feUI3SzB6bzBHVDFva04tdnpqSmYzOXdFbG1US0trQndfWVA4MDBwYVEyUkdlUlZjVEx1em9zc2pZSzFZTlZaU1pnZjFncWxvRXVwX09abk9jTjEwcXMybUtfN2RFbDNuSEp3VHdJWng2NmlueEoyS0MxV0cxLUFUd0t3WjRPdThtd2JMWGJIX3Bhekg2SC15MW9VVmJVLUVFZGVXRmxwMW1CY3QyZTRzc1VEV3B6YW5CM25nN2E5RnpHNFZRV1BGWTlpcWstX3BXQjVjU1ZEbzEtY1o4VzIxY2xRUkxlR0hIU21yQTNjdEE?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-15T07:00:00+00:00", "published_display": "15 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avidity Biosciences Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPeFhRUF8wT0VzcmNQSlVTUlE5eEpuMzdTWFE4QkJfaVlnMGt4QU5CcHdHSDYyaHh3Q1lDZ1FuZXlsQjQ4V0k3R3B3V21iMG5fZVlUSjJYS3hNTFJGMUFpdUpnN2lmenJlZkszeDh0Rm55UmZJV0RHWFNhdVAxaEktTmRrSUNNa1hWa0l2eG51VXZqWlVKWnVkdWc0WVptUnZVNVJOZXN2UFJVSkZfNkREdlJ3ako3cU44cGpRRWFhNVhHakZy?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9ELTZtY1Z1Y0VsTHhQZWkwaWFfTUpvS21fUDhGU3M3c0Y1TDdGdGgzV2tmeXluUkNXZkVDdzRkU2JtWHdvX1N4V0pwU3VGb1dlVl9qbUlCekpRMzhDaXdMa05HaGFrdnBfTDFBcWZOZmd3WHZGZ091RA?oc=5", "source_name": "Market source", "published_at": "2025-08-25T07:00:00+00:00", "published_display": "25 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 47, "sentiment_summary": {"positive": 10, "negative": 3, "neutral": 34, "score": 54, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 12.45, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 9.15, "count": 18}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 12.15, "latest_week": "2026-07-17", "one_week_move": -2.5, "four_week_move": -4.0, "twelve_week_move": -9.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -8.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.8011, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.5% over one week, -4.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 5}, {"label": "PR Newswire", "count": 5}, {"label": "TradingView", "count": 3}, {"label": "TradingKey", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "TIKR.com", "count": 2}, {"label": "Barron's", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 18}, {"label": "Deals and strategy", "count": 4}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.5% over one week, -4.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Atrium Therapeutics\u2019 new hire receives options and 3,500 stock units"}], "updated_at": "2026-07-23T03:36:55.754292+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}